Back to top
more

InfuSystems Holdings (INFU)

(Delayed Data from AMEX)

$5.70 USD

5.70
92,083

+0.10 (1.79%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $5.72 +0.02 (0.35%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (174 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is the Options Market Predicting a Spike in InfuSystems Holdings Stock?

by Zacks Equity Research

Investors need to pay close attention to InfuSystems Holdings stock based on the movements in the options market lately.

Zacks Equity Research

Neogen (NEOG) Q4 Earnings Lag Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -37.50% and +1.90%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InfuSystems Holdings, Inc. (INFU) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

InfuSystems Holdings (INFU) delivered earnings and revenue surprises of 66.67% and 4.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Options Traders Betting on a Big Move in InfuSystem (INFU) Stock?

by Zacks Equity Research

Investors need to pay close attention to InfuSystem (INFU) stock based on the movements in the options market lately.

Zacks Equity Research

InfuSystems Holdings, Inc. (INFU) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

InfuSystems Holdings (INFU) delivered earnings and revenue surprises of -50% and 1.61%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of -16.67% and 4.42%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge

by Zacks Equity Research

Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.

Zacks Equity Research

Analysts Estimate InfuSystems Holdings, Inc. (INFU) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

InfuSystems Holdings, Inc. (INFU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

InfuSystems Holdings, Inc. (INFU) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

InfuSystems Holdings, Inc. (INFU) delivered earnings and revenue surprises of -63.64% and -9.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate InfuSystems Holdings, Inc. (INFU) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

InfuSystems Holdings, Inc. (INFU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in InfuSystems Holdings, Inc. (INFU): Can Its 14.2% Jump Turn into More Strength?

by Zacks Equity Research

InfuSystems Holdings, Inc. (INFU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.